BX-004 is a biologic commercialized by BiomX, with a leading Phase II program in Cystic Fibrosis. According to Globaldata, it is involved in 1 clinical trial, which is ongoing. GlobalData uses proprietary data and analytics to provide a complete picture of BX-004’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
The revenue for BX-004 is expected to reach an annual total of $30 mn by 2038 globally based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
BX-004 is under development for the treatment of cystic fibrosis and resistant pseudomonas aeruginosa infections. It is administered as inhalational formulation. The drug candidate comprises of cocktail of natural phages developed based on BOLT (Bacteriophage Lead to Treatment) platform.
BiomX is a microbiome company that developing natural and engineered phage cocktails targeting harmful bacteria in chronic diseases and conditions such as acne, inflammatory bowel disease (IBD), liver disease. The company’s lead product candidate includes BX003to treat primary sclerosing cholangitis (PSC). BiomX CRC program helps in recognizing and validating associations of specific strains of bacteria. The company BX005 is topical phage product candidate which targeting Staphylococcus aureus. It works in collaboration with Massachusetts Institute of Technology, Janssen Pharmaceuticals, Takeda Pharmaceutical Co Ltd, JSR Corporation and Weizmann Institute of Science. BiomX is headquartered in Ness Ziona, Israel.
The operating loss of the company was US$27.2 million in FY2022, compared to an operating loss of US$35.5 million in FY2021. The net loss of the company was US$28.3 million in FY2022, compared to a net loss of US$36.2 million in FY2021.
For a complete picture of BX-004’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.